Moderna and Merck shares rise after cancer vaccine results

A successful study has demonstrated that a vaccine against advanced skin cancer based on mRNA technology could open new horizons for treating this disease. The study showed that the vaccine enhances the immune system's ability to recognize and destroy cancer cells after surgical procedures, representing a major breakthrough in cancer treatment. Following the announcement, Moderna's stock rose by 177%, surpassing market expectations, with prospects that mRNA technology could be used for treatments of other types of cancers, potentially significantly supporting the targeted pharmaceutical market.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل